Previous 10 |
Dicerna Pharmaceuticals, Inc. (DRNA) Q3 2018 Results Earnings Conference Call November 05, 2018, 04:30 PM ET Executives Paula Schwartz - Investor Relations Douglas Fambrough - President and CEO Jack Green - CFO Ralf Rosskamp - Chief Medical Officer Analysts Stephen Willey...
Dicerna Pharmaceuticals (NASDAQ: DRNA ): Q3 GAAP EPS of -$0.35 misses by $0.09 . More news on: Dicerna Pharmaceuticals, Inc., Earnings news and commentary, Healthcare stocks news, Read more ...
Demonstrated Clinical POC for DCR-PHXC in Primary Hyperoxaluria and On Track to Initiate Registration Trial in Q1 2019 Entered into Strategic Collaborations with Lilly and Alexion to Discover and Develop RNAi Therapies Using Dicerna’s GalXC™ Technology Platform Close...
Recently, Dicerna Pharmaceuticals ( DRNA ) announced a partnership with Eli Lilly ( LLY ) which amounts to an upfront payment and an equity stake . This is just one of the most recent validations of Dicerna's GalXC technology. Just this past week, Dicerna garnered another deal with Ale...
Dicerna Pharmaceuticals, Inc. (NASDAQ: DRNA), a leading developer of investigational ribonucleic acid interference (RNAi) therapeutics, today announced that the Company will release its third quarter 2018 financial results after market close on Monday, November 5, 2018. Management will...
Red Hat (NYSE: RHT ) +49% on being acquired by IBM. More news on: Red Hat, Inc., Diana Containerships Inc., China Recycling Energy Corporation, Stocks on the move, , Top stock market news, Read more ...
Eli Lilly (NYSE: LLY ) and Dicerna Pharmaceuticals (NASDAQ: DRNA ) ink a global licensing and research collaboration agreement aimed at discovering, developing and commercializing new RNAi therapeutics in cardio-metabolic disease, neurodegeneration and pain. The partnership will leverage D...
INDIANAPOLIS and CAMBRIDGE, Mass. , Oct. 29, 2018 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) and Dicerna Pharmaceuticals (NASDAQ: DRNA) today announced a global licensing and research collaboration focused on the discovery, development and commercialization of potential new medic...
Single-dose Data from Ongoing PHYOX Phase 1 Trial, Presented at ASN Kidney Week, Show Normalization or Near-normalization of Urinary Oxalate Levels in a Majority of Participants Reductions in Urinary Oxalate, Combined with Favorable Safety/Tolerability Profile, Lay Groundwork for Plann...
News, Short Squeeze, Breakout and More Instantly...
Dicerna Pharmaceuticals Inc. Company Name:
DRNA Stock Symbol:
NASDAQ Market:
Dicerna Pharmaceuticals Inc. Website:
Novo Nordisk today announced that the acquisition of Dicerna Pharmaceuticals, Inc. (Dicerna; Nasdaq: DRNA), announced on 18 November 2021, has been completed. Following the expiration of Novo Nordisk’s cash tender offer for Dicerna, Novo Nordisk has today acquired all outstan...
Dicerna Pharmaceuticals, Inc. (Nasdaq: DRNA) today announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended (“HSR”), in connection with Novo Nordisk’s cash tender offer for Dicerna expired at 11:59 p.m., Easter...
Direxion Launches mRNA ETF (MSGR) MSGR Offers Exposure to Rapidly Evolving mRNA Sector PR Newswire NEW YORK , Dec. 9, 2021 /PRNewswire/ -- Direxion announced today the launch of the Direxion mRNA ETF (Ticker: MSGR) . MSGR invests in companies ...